Researchers at the Icahn School of Medicine at Mount Sinai have been awarded an initial $16 million from the National Institutes of Health (NIH) to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.
Scientists from St. Jude Children’s Research Hospital and the International Society of Paediatric Oncology report results from the Global Registry of COVID-19 and Childhood Cancer.
Rush University Medical Center is opening an advanced molecular laboratory that will examine COVID-19 samples from across the city to detect new strains of the virus for the Chicago Department of Public Health
Since the first cases of COVID-19 were detected in the U.S. nearly one year ago, board-certified dermatologists have been on the front lines helping to treat patients and furthering the medical community’s understanding of the virus. The following dermatologists and…
A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.
Study is the basis of a new international clinical trial
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Rutgers faculty receive grant to study how the current pandemic impacts people living with HIV, who may be at heightened risk for severe illness from COVID-19 compared to the general population.
An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is underway at Memorial Hermann and Harris Health System’s Lyndon B. Johnson Hospital.
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG
Announcement of the Harrington Discovery Institute and Morgan Stanley raising funds for furthering COVID-19 research.
Findings from an online survey of more than 53,000 American adults suggest that using heartburn medications known as proton pump inhibitors (PPIs) once or twice daily significantly increases the odds of a positive test for COVID-19 compared to those who do not take PPIs. This research appeared online July 7, 2020 in pre-print format in The American Journal of Gastroenterology.